Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer

Clinical Genitourinary Cancer

Volumn 15, Issue 1, 2017, Pages e65-e68

  Tosoian, Jeffrey J ^a   Gorin, Michael A ^a   Rowe, Steven P ^a   Andreas, Darian ^a   Szabo, Zsolt ^a   Pienta, Kenneth J ^a   Pomper, Martin G ^a   Lotan, Tamara L ^a   Ross, Ashley E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunohistochemistry (IHC); Metastatic prostate cancer; Neuroendocrine prostate cancer; Positron emission tomography computed tomography (PET CT) imaging; Prostate specific membrane antigen

Indexed keywords

BICALUTAMIDE; CARBOPLATIN; DCFPYL F 18; DOCETAXEL; ETOPOSIDE; LEUPRORELIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SIPULEUCEL T; TRACER; UNCLASSIFIED DRUG; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LYSINE; MEMBRANE ANTIGEN; PROTEIN P53; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; TP53 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; UREA;

AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CORRELATION ANALYSIS; DRUG SUBSTITUTION; GENOMICS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; METASTATIC NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SPINE METASTASIS; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; MOLECULAR IMAGING; MUTATION; PROSTATE TUMOR;

AGED; ANTIGENS, SURFACE; CARCINOMA, NEUROENDOCRINE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYSINE; MALE; MOLECULAR IMAGING; MUTATION; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RETINOBLASTOMA BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UREA;

EID: 85001831561     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.09.002     Document Type: Article

References (16)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. 2 Kiess, A.P., Cho, S.Y., Pomper, M.G., Translational molecular imaging of prostate cancer. Curr Radiol Rep 1 (2013), 216–226.
3. 3 Kiess, A., Banerjee, S., Mease, R., et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging 59 (2016), 241–268.
4. 4 Rowe, S.P., Gorin, M.A., Allaf, M.E., et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19 (2016), 223–230.
5. 5 Hansel, D.E., Nakayama, M., Luo, J., et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69 (2009), 603–609.
6. 6 Zhou, Z., Flesken-Nikitin, A., Corney, D.C., et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66 (2006), 7889–7898.
7. 7 Tan, H.L., Sood, A., Rahimi, H.A., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20 (2014), 890–903.
8. 8 Minner, S., Wittmer, C., Graefen, M., et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate 71 (2011), 281–288.
9. 9 Ananias, H.J.K., van den Heuvel, M.C., Helfrich, W., de Jong, I.J., Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69 (2009), 1101–1108.
10. 10 Szabo, Z., Mena, E., Rowe, S.P., et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 17 (2015), 565–574.
11. 11 Dietlein, M., Kobe, C., Kuhnert, G., et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17 (2015), 575–584.
12. 18F PET/CT?. Clin Genitourin Cancer 14 (2016), e115–e118.
13. 13 Rowe, S.P., Macura, K.J., Mena, E., et al. PSMA-Based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol 18 (2016), 411–419.
14. 14 Chakraborty, P.S., Tripathi, M., Agarwal, K.K., Kumar, R., Vijay, M.K., Bal, C., Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation. Clin Nucl Med 40 (2015), e163–e166.
15. 15 Tsai, H., Morais, C.L., Alshalalfa, M., et al. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res 21 (2015), 5619–5629.
16. 16 Clegg, N., Ferguson, C., True, L.D., et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55 (2003), 55–64.